Sanofi - Product Pipeline Review - 2016

  • ID: 3714998
  • Company Profile
  • 203 pages
  • Global Markets Direct
  • Sanofi S.A.
1 of 4
Sanofi - Product Pipeline Review - 2016

Summary

‘Sanofi - Product Pipeline Review - 2016’, provides an overview of the Sanofi’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sanofi, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sanofi
- The report provides overview of Sanofi including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sanofi’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sanofi’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Sanofi’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sanofi
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sanofi’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Sanofi Snapshot

Sanofi Overview

Key Information

Key Facts

Sanofi - Research and Development Overview

Key Therapeutic Areas

Sanofi - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Sanofi - Pipeline Products Glance

Sanofi - Late Stage Pipeline Products

Sanofi - Clinical Stage Pipeline Products

Sanofi - Early Stage Pipeline Products

Sanofi - Drug Profiles

(insulin glargine + lixisenatide)

lixisenatide

mipomersen sodium

semuloparin sodium

(fexofenadine hydrochloride + phenylephrine hydrochloride)

avanafil

cabazitaxel

insulin lispro

ziv-aflibercept (recombinant)

fexinidazole

(capecitabine + cyclophosphamide)

alemtuzumab

artefenomel + ferroquine

ataciguat

efpeglenatide

isatuximab

plerixafor

SAR-156597

sotagliflozin

pilaralisib

SAR-408701

SAR-421869

SAR-422459

voxtalisib

Monoclonal Antibodies to Inhibit Abeta for Alzheimer's Disease

SAR-113244

SAR-228810

SAR-366234

SAR-407899

SAR-425899

SAR-428926

SAR-438335

SAR-438544

SAR-440067

SAR-566658

ACP-003

DCM-1

efpeglenatide + HM-12470

food allergy vaccine

Peptides for Tuberculosis

Recombinant Proteins for Pseudomonas aeruginosa Infection

SAR-088

SAR-110068

SAR-131675

SAR-156497

SAR-184841

SAR-216471

SAR-224

SAR-244181

SAR-296968

SAR-396049

SAR-7334

Small Molecule 4 for Tuberculosis

Small Molecule to Inhibit Beta Sliding Clamp for Tuberculosis

Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds

Monoclonal Antibodies for Infectious Disease

Monoclonal Antibodies for Neurodegenerative Diseases

Peptide for HIV and HSV Infections

SAR-405

Small Molecule 2 for Tuberculosis

Small Molecule 3 for Tuberculosis

Small Molecule for Calcific Aortic Valve Stenosis

Small Molecule for Duchenne Muscular Dystrophy

Small Molecules for Malaria

Small Molecules to Inhibit Protein Kinase for Undisclosed Indication

Vaccine for Celiac Disease

Vaccine for Food Allegy 2

Zika virus vaccine

Sanofi - Pipeline Analysis

Sanofi - Pipeline Products by Target

Sanofi - Pipeline Products by Route of Administration

Sanofi - Pipeline Products by Molecule Type

Sanofi - Pipeline Products by Mechanism of Action

Sanofi - Recent Pipeline Updates

Sanofi - Dormant Projects

Sanofi - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Sanofi - Company Statement

Sanofi - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Sanofi - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Sanofi, Key Information

Sanofi, Key Facts

Sanofi - Pipeline by Indication, 2016

Sanofi - Pipeline by Stage of Development, 2016

Sanofi - Monotherapy Products in Pipeline, 2016

Sanofi - Combination Treatment Modalities in Pipeline, 2016

Sanofi - Partnered Products in Pipeline, 2016

Sanofi - Partnered Products/ Combination Treatment Modalities, 2016

Sanofi - Out-Licensed Products in Pipeline, 2016

Sanofi - Out-Licensed Products/ Combination Treatment Modalities, 2016

Sanofi - Pre-Registration, 2016

Sanofi - Filing rejected/Withdrawn, 2016

Sanofi - Phase III, 2016

Sanofi - Phase II, 2016

Sanofi - Phase I, 2016

Sanofi - Preclinical, 2016

Sanofi - Discovery, 2016

Sanofi - Pipeline by Target, 2016

Sanofi - Pipeline by Route of Administration, 2016

Sanofi - Pipeline by Molecule Type, 2016

Sanofi - Pipeline Products by Mechanism of Action, 2016

Sanofi - Recent Pipeline Updates, 2016

Sanofi - Dormant Developmental Projects,2016

Sanofi - Discontinued Pipeline Products, 2016

Sanofi, Subsidiaries

Sanofi, Key Manufacturing Facilities

List of Figures

Sanofi - Pipeline by Top 10 Indication, 2016

Sanofi - Pipeline by Stage of Development, 2016

Sanofi - Monotherapy Products in Pipeline, 2016

Sanofi - Combination Treatment Modalities in Pipeline, 2016

Sanofi - Partnered Products in Pipeline, 2016

Sanofi - Out-Licensed Products in Pipeline, 2016

Sanofi - Pipeline by Top 10 Target, 2016

Sanofi - Pipeline by Route of Administration, 2016

Sanofi - Pipeline by Top 10 Molecule Type, 2016

Sanofi - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll